Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-11-07
2006-11-07
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S106000, C544S162000, C546S184000, C546S246000, C546S329000, C546S334000, C548S566000, C514S231200, C514S408000
Reexamination Certificate
active
07132422
ABSTRACT:
The invention provides sodium channel modulating compounds which are useful for treating diseases or conditions associated with sodium channel activity, such as neuropathic pain. The invention also provides pharmaceutical compositions comprising a compound of the present invention, as well as therapeutic methods comprising administering such a compound or salt to a mammal (e.g. a human).
REFERENCES:
patent: 4140779 (1979-02-01), Ferland et al.
patent: 4386090 (1983-05-01), Moinet et al.
patent: 5688830 (1997-11-01), Berger et al.
patent: 5985933 (1999-11-01), Zeitlin et al.
patent: 6646012 (2003-11-01), Choi et al.
patent: 6756400 (2004-06-01), Chinn et al.
patent: 6872741 (2005-03-01), Choi et al.
patent: 2004/0204460 (2004-10-01), Chinn et al.
patent: 0 869 119 (1998-10-01), None
patent: 2 496 653 (1982-06-01), None
patent: WO 97/27169 (1997-07-01), None
De Luca et al., “Molecular Determinants of Mexiletine Structure for Potent and Use-Dependent Block of Skeletal Muscle Sodium Channels”, Molecular Pharmacology, vol. 57, pp. 268-277 (2000).
Hunter et al., “Voltage-gated sodium channel blockers for the treatment of chronic pain”, Current Opinion in CPNS Investigational Drugs, vol. 1(1), pp. 72-81 (1999).
Loughhead et al., “Synthesis of Mexiletiine Stereoisonomers and Related Compounds via SNAr Nucleophilic Substitution of a Cr(CO)3-Complexed Aromatic Fluoride”, J. Org. Chem., vol. 64, pp. 3373-3375 (1999).
Madge, “Chapter 6. Sodium Channels: Recent Developments and Therapeutic Potential”, Annual Reports in Medicinal Chemistry, pp. 51-59 (1998).
Roufos et al., “A Structure-Activity Relationship Study of Novel Phenylacetamides Which Are Sodium Channel Blockers”, J. Med. Chem., vol. 39, pp. 1514-1520 (1996).
Zaagama, “β-Adrenoceptor Studies. 51H NMR and IR Spectroscopic Analysis of the Conformation of the Hydrohalide Salts of β-Adrenoceptor-Blocking Aryloxypropanolamines. Evidence for a Seven-Membered Ring Structure with Participation of Two Hydrogen Bonds”, J. Med. Chem., vol. 22, No. 4, pp. 441-449 (1979).
Choi Seok-Ki
Fatheree Paul R.
Green David C.
Marquess Daniel
Hagenah Jeffrey A.
Shameem Golam M. M.
Theravance Inc.
LandOfFree
Sodium channel modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sodium channel modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sodium channel modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3695472